SEC Form 4 · accession 0001654954-17-004119
Cellular Biomedicine Group, Inc. · CBMG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yihong Yao
Officer — Chief Scientific Officer
Period of report
Apr 27, 2017
Accepted (ET)
May 5, 2017 · 2:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001378624
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 27, 2017 | F | 199 | $10.70 | D | 26,381 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person was granted 26,500 restricted stock units ("RSUs") (Grant No. LTIP RSU G4) under the Cellular Biomedicine Group, Inc. 2014 Stock Incentive Plan, which RSUs vest over a period of four years according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017. On April 27, 2017, 552 RSUs vested and were delivered to the Reporting Person, of which 199 shares of common stock were withheld (at the closing price of the Company's common stock on the NASDAQ Global Market on Thursday, April 27, 2017) to satisfy the tax obligation relating to the vesting of the RSUs pursuant to Section 16b-3(e) under the Securities Exchange Act of 1934.